COVID-19 Associated Pulmonary Aspergillosis (CAPA)—From Immunology to Treatment
Top Cited Papers
Open Access
- 24 June 2020
- journal article
- review article
- Published by MDPI AG in Journal of Fungi
- Vol. 6 (2), 91
- https://doi.org/10.3390/jof6020091
Abstract
Like severe influenza, coronavirus disease-19 (COVID-19) resulting in acute respiratory distress syndrome (ARDS) has emerged as an important disease that predisposes patients to secondary pulmonary aspergillosis, with 35 cases of COVID-19 associated pulmonary aspergillosis (CAPA) published until June 2020. The release of danger-associated molecular patterns during severe COVID-19 results in both pulmonary epithelial damage and inflammatory disease, which are predisposing risk factors for pulmonary aspergillosis. Moreover, collateral effects of host recognition pathways required for the activation of antiviral immunity may, paradoxically, contribute to a highly permissive inflammatory environment that favors fungal pathogenesis. Diagnosis of CAPA remains challenging, mainly because bronchoalveolar lavage fluid galactomannan testing and culture, which represent the most sensitive diagnostic tests for aspergillosis in the ICU, are hindered by the fact that bronchoscopies are rarely performed in COVID-19 patients due to the risk of disease transmission. Similarly, autopsies are rarely performed, which may result in an underestimation of the prevalence of CAPA. Finally, the treatment of CAPA is complicated by drug–drug interactions associated with broad spectrum azoles, renal tropism and damage caused by SARS-CoV-2, which may challenge the use of liposomal amphotericin B, as well as the emergence of azole-resistance. This clinical reality creates an urgency for new antifungal drugs currently in advanced clinical development with more promising pharmacokinetic and pharmacodynamic profiles.Keywords
This publication has 104 references indexed in Scilit:
- Cleavage of Fibrinogen by Proteinases Elicits Allergic Responses Through Toll-Like Receptor 4Science, 2013
- Hidden Killers: Human Fungal InfectionsScience Translational Medicine, 2012
- DAMP signaling in fungal infections and diseasesFrontiers in Immunology, 2012
- Genetically-Determined Hyperfunction of the S100B/RAGE Axis Is a Risk Factor for Aspergillosis in Stem Cell Transplant RecipientsPLOS ONE, 2011
- Evidence that TMPRSS2 Activates the Severe Acute Respiratory Syndrome Coronavirus Spike Protein for Membrane Fusion and Reduces Viral Control by the Humoral Immune ResponseJournal of Virology, 2011
- The Danger Signal S100B Integrates Pathogen– and Danger–Sensing Pathways to Restrain InflammationPLoS Pathogens, 2011
- MyD88 Is Required for Protection from Lethal Infection with a Mouse-Adapted SARS-CoVPLoS Pathogens, 2008
- Invasive pulmonary aspergillosis in chronic obstructive pulmonary disease: an emerging fungal pathogenClinical Microbiology & Infection, 2005
- Impaired Antifungal Effector Activity but Not Inflammatory Cell Recruitment in Interleukin‐6–Deficient Mice with Invasive Pulmonary AspergillosisThe Journal of Infectious Diseases, 2001
- Proteases fromAspergillus fumigatusInduce Interleukin (IL)–6 and IL‐8 Production in Airway Epithelial Cell Lines by Transcriptional MechanismsThe Journal of Infectious Diseases, 1999